InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference
09 Setembro 2022 - 9:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a
research and clinical-stage biomaterials and biotechnology company
with a focus on the treatment of spinal cord injuries, today
announced that Richard Toselli, M.D., President and Chief Executive
Officer, will present at the upcoming H.C. Wainwright 24th Annual
Global Investment Conference, which runs from September 12 – 14,
2022. Dr. Toselli and company management will also be available to
participate in virtual one-on-one meetings with registered
investors attending the conference.
A webcast of Dr. Toselli’s presentation will be available on the
Investor Relations - Events section of the company website at
https://investors.invivotherapeutics.com/events, beginning
September 12, 2022 at 7:00 am ET.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. The
publicly traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220909005020/en/
Investor Contact:
Bret Shapiro, Managing Partner CORE IR brets@coreir.com (516)
222-2560
Media Contact
Tom Donovan Ten Bridge Communications
tom@tenbridgecommunications.com (857) 559-3397
InVivo Therapeutics (NASDAQ:NVIV)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
InVivo Therapeutics (NASDAQ:NVIV)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024